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Summary 
Tuberculosis has been an endemic disease in Taiwan for decades. After the Second 
World War, a vertical tuberculosis program was established. Tuberculosis services in 
Taiwan from 1950s -1990s partly reflected the evolution of international tuberculosis 
control policy but had its unique development, challenges and achievements. 
Tuberculosis mortality and prevalence declined substantially from 1950s -1990s in 
Taiwan. However, it became increasingly difficult to provide tuberculosis services 
through a vertical program after implementing the national health insurance 
program in 1995. The government of Taiwan dismantled the vertical tuberculosis 
program in 2001 and integrated tuberculosis services into the general health care 
system, which presented an opportunity for strengthening tuberculosis services but 
also implied threats of disintegration. Constraints needed to be identified and 
addressed to ensure efficiency and effectiveness of this fully integrated approach. 
This thesis reports on a series of studies of the operation of the services and 
demonstrates that (1) the quality of smear microscopy in a few laboratories in 2004 
was not satisfactory; (2) tuberculosis-related death without treatment in Taipei in 
2003 was substantial; (3) a high proportion of tuberculosis patients were treated 
with anti-tuberculosis drugs on the basis of radiographic findings in Taipei in 2003 
and subsequently were advised to stop anti-tuberculosis treatment before 
completion; (4) prescribing practices for anti-tuberculosis drugs in the treatment of 
tuberculosis in Taipei in 2003 was substandard; (5) treatment interruption for 2 
consecutive months and sputum positive at 5 months or later was largely 
under-detected; and (6) there was substantial misclassification of notified 
tuberculosis cases in Taipei in 2003. Findings of these studies resulted in corrective 
actions and policy changes undertaken by health authorities to strengthen 
tuberculosis services in Taiwan.  
 12
1. Introduction 
 
1.1 Mycobacterium tuberculosis and tuberculosis disease 
 
The agent causing tuberculosis in humans is mainly Mycobacterium tuberculosis (M. 
tuberculosis). Tuberculosis is thought to have 2 distinct stages, namely latent 
infection with M. tuberculosis and active tuberculosis disease. Persons who are 
exposed to infectious tuberculosis patients are at risk of infection with M. 
tuberculosis. The probability of infection, given exposure, is determined by the 
infectiousness of the source case, the characteristics of the environment in which 
exposure takes place, the duration of exposure, and probably also the virulence of 
the tubercle bacilli.1 Once infected, the risk of progression to active tuberculosis 
disease is largely determined by the ability of the immune system to contain or 
eliminate tubercle bacilli. The risk is highest within the first year after acquiring 
infection. Children under 5 years of age have a higher risk of progression because of 
immaturity of the immune system.2 Human immunodeficiency virus infection is a 
strong risk factor in reactivating latent infection and rapid progression of recent 
infection.3 There is no permanent protective immunity against re-infection.4 Given 
exposure, persons who have been previously infected with tuberculosis are still at 
risk of re-infection.    
 
1.2 Treatment of tuberculosis  
 
There was no specific treatment of tuberculosis till the 1940s when streptomycin5 
and para-aminosalicylic acid6, 7 were introduced. It was soon realized that treatment 
of tuberculosis using a single drug results in decline of drug susceptible bacilli and 
predominant replication of drug-resistant mutants, and that multiple drugs should be 
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used simultaneously to avoid the emergence of drug-resistant tuberculosis.8 In the 
1950s, some experts believed that tuberculosis could only be suppressed for a period 
of time but was not curable. Crofton demonstrated that adequate treatment of 
tuberculosis resulted in a dramatic fall in deaths from tuberculosis and had an impact 
on the number of new cases of tuberculosis in Edinburgh; he argued that it is 
possible to aim at 100% success in the treatment of pulmonary tuberculosis.9, 10 
Subsequently, several clinical trials were conducted,11 eventually demonstrating that 
rifampicin-based short-course chemotherapy is highly efficacious with a high cure 
rate and low relapse rate, and this formed the basis of modern tuberculosis control. 
Unfortunately, drug-resistant tuberculosis may emerge during anti-tuberculosis 
treatment. Factors associated with drug-resistant tuberculosis include inadequate 
regimens, inconsistent dosing, poor quality of drugs, and poor adherence to 
treatment.12 Multidrug-resistant tuberculosis (MDR-TB), defined as tuberculosis 
caused by M. tuberculosis that is resistant to at least isoniazid and rifampicin, is 
difficult and expensive to treat and poses huge challenges to tuberculosis services.13, 14
 
 
1.3 Principles of tuberculosis service 
 
Tuberculosis services aim at reducing the transmission of tuberculosis in a 
community. Smear-positive cases have been shown to be the most powerful source 
of transmission.15 Interventions for tuberculosis control and elimination include 
chemotherapy of tuberculosis, vaccination with Bacille Calmette-Guérin (BCG), and 
preventive therapy,16 as well as addressing social determinants and managing risk 
factors.17 Vaccination against tuberculosis using BCG has been recommended by 
United Nations Children's Fund (UNICEF) and World Health Organization (WHO) since 
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the 1940s; at that time, it was the most feasible intervention that could be 
implemented on a large scale. The International Tuberculosis Campaign that started 
in the war-torn areas of Europe administered BCG to 14 million persons.18, 19 However, 
the efficacy of BCG in preventing tuberculosis varied across settings.20 BCG 
vaccination might reduce the risk of severe tuberculosis (tuberculosis meningitis and 
miliary tuberculosis) in children21 but has limited impact on the transmission of 
tuberculosis, especially if the risk of infection is high.22  
 
Preventive chemotherapy is efficacious in reducing the risk of tuberculosis23 and has 
been used extensively in the United States24 and several developed countries. 
However, it is difficult to ensure adherence to preventive chemotherapy.25 Further, 
persons who complete a course of preventive chemotherapy are still at risk of 
re-infection.26 Therefore, preventive chemotherapy has not yet been widely applied 
for tuberculosis control in developing countries, including most settings with a high 
prevalence of HIV infection.27 Addressing social determinants (such as poverty), 
improving access to care of vulnerable groups and marginalized populations,28 
reducing the prevalence of risk factors (such as reducing the prevalence of smoking 
through implementing Framework Convention of Tobacco Control)29 and reducing 
the impact of risk factors on the development of tuberculosis (such as reducing the 
risk of tuberculosis among the HIV-infected by anti-retroviral therapy)30 may 
contribute to tuberculosis control.    
 
The tools that are most commonly used in the diagnosis of tuberculosis are chest 
radiography and sputum bacteriological examination.31 Under-reading and 
over-reading have been concerns in the use of the chest radiograph. An international 
study on the classification of chest radiograph readings demonstrated a high degree 
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of disagreement on reading chest radiographs among 90 experts.32 Thereafter, it was 
commonly agreed that the chest radiograph cannot be used alone in the diagnosis of 
pulmonary tuberculosis. Studies of indiscriminate mass radiography, which was 
applied for tuberculosis case-finding in the 1950s-1960s, also contributed to a shift of 
focus from chest radiography to the mycobacteriology laboratory in tuberculosis 
services. The rationale for mass radiography was to detect tuberculosis cases at an 
early stage before progressing to becoming smear-positive by periodic screening 
repeated at short intervals.33 However, mass radiography identified only a small 
proportion of smear-positive incident cases. The majority of smear-positive cases 
were diagnosed among symptomatic patients who presented themselves to health 
care services.34 Further, the proportion of smear-positive cases in a population 
remained relatively unchanged after repeated screening.33 Therefore, indiscriminate 
mass radiography was replaced by other approaches.35  
 
In the 1970s, Grzybowski and Enarson36 investigated the fate of tuberculosis cases in 
different programs and reported that inadequate treatment failing to achieve a high 
proportion of treatment success prolonged the duration of infectiousness of 
tuberculosis patients, which may potentially make the epidemic of tuberculosis even 
worse than with no treatment. This finding triggered the development of 
International Union Against Tuberculosis (IUAT) model program, which aimed, as a 
first priority, at achieving a high cure rate. The current basis of tuberculosis control is 
to efficiently detect infectious tuberculosis cases, especially smear-positive cases, 
and render them non-infectious by effective anti-tuberculosis treatment. The 
objective is to create an “infection-free” generation that will eventually lead to the 
elimination of tuberculosis.37 
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1.4 Evolution of global policies for tuberculosis control 
 
Policies for global tuberculosis control have evolved in recent decades.38-40 The first 
World Health Assembly in 1948 recommended that governments take preventive, 
curative, legislative, and social measures for tuberculosis control. Services of 
diagnosis and treatment of tuberculosis were mainly provided through a vertical 
approach characterized by a central tuberculosis unit that directly operated several 
specialized hospitals and tuberculosis clinics, and a specialized program operated 
through its own officers for training, supervision, logistics, and offered its own 
laboratory services.39 In 1964, the principles of modern tuberculosis control were 
formulated in a WHO Expert Committee of Tuberculosis Eighth Report,41 in which 
development and implementation of the national tuberculosis program (NTP) 
comprising case-finding and treatment, with particular emphasis on smear-positive 
cases, and mass BCG vaccination, were recommended. Thereafter, integration of 
service delivery took place, in which the delivery of case management activities was 
operated through the general health services, but the specialized approach was kept 
intact for the managerial functions; tuberculosis control experts continued to be 
responsible for training, supervision, logistics, health education, and evaluation. The 
recommendation for the implementation of NTP was re-iterated and expanded 10 
years later in WHO Expert Committee of Tuberculosis Ninth Report.35 In 1978, a 
conference on Primary Health Care as the framework of health development was 
held in Alma Alta, in which equity, community participation, health promotion, 
inter-sectoral collaboration, and appropriate use of resources were highly promoted 
under the slogan “Health for all by the year 2000”.42, 43 Consequently, further steps in 
integration of managerial functions of tuberculosis and other programs were 
undertaken, driven by general public-health experts and primary health care 
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promoters. Unfortunately, the quality of tuberculosis case-finding and treatment 
deteriorated, partly because general health experts without proper training were 
unable to provide adequate supervision and training for tuberculosis control. During 
that period, Styblo, inspired by the report that poor treatment is worse than no 
treatment,36, 44 pilot tested the IUAT collaborative program in Tanzania and several 
other developing countries, aiming to achieve a high cure rate and to avoid creating 
chronic tuberculosis cases harboring drug-resistant tuberculosis.45, 46 The approach 
taken by Styblo underscoring the importance of ensuring a high cure rate was a 
paradigm shift, departing from previous approach that emphasized tuberculosis case 
finding. In the 1990s, the innovative approaches of the IUAT collaborative program47 
was ranked as one of the most cost-effective public health intervention in developing 
countries by the World Bank .48, 49 WHO re-focused on tuberculosis, adopted IUAT 
collaborative model program as a new framework of a global tuberculosis control 
strategy, and re-directed global tuberculosis control policy back to a specialized 
managerial approach, in which specialized managerial functions at central, regional, 
and district levels was re-established but the principles of integration of service 
delivery into the primary health care infrastructure were maintained.50-52 In 1993, 
tuberculosis was declared a global emergency and in 1994, a new framework for 
tuberculosis control was published,50 which kick-started a new era of global 
tuberculosis control. Most countries re-structured national tuberculosis programs to 
implement the ‘directly-observed treatment short-course’ (nicknamed “DOTS” by 
WHO) strategy. 53-64 Targets were set to detect 70% of existing cases and to achieve 
85% successful treatment, and subsequently were expanded with an aim to half 
mortality and prevalence of tuberculosis as well as to reverse the incidence of 
tuberculosis by 2015 as compared with that in 1990 as baseline. Global tuberculosis 
reports have been published annually to keep track of progress in global tuberculosis 
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control. A Stop Tuberculosis Partnership was established. A global plan to stop 
tuberculosis was developed. New funding mechanisms, such as the Global Fund to 
Fight AIDS, Tuberculosis and Malaria, were born. In 2006, the Stop Tuberculosis 
Strategy was launched, expanding on the former DOTS strategy.65  
 
1.5 Taiwan: land and people 
 
 
Figure 1. Map of Taiwan and Asia Pacific. (Source: Google map 
http://maps.google.com/maps?hl=zh-TW&q=taiwan%20map%20in%20english&bav=
on.2,or.r_gc.r_pw.,cf.osb&biw=1680&bih=920&wrapid=tlif133144224921811&um=1
&ie=UTF-8&sa=N&tab=wl ) 
 
Taiwan is an island of East Asia located in the western Pacific Ocean off the 
southeastern coast of China. It has a land mass of 36,000 square kilometers. The 
majority of inhabitants are Han people from the mainland of China and a minority 
Taiwan 
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are aboriginal (Austronesian) people (about 2%). Taiwan was ceded to Japan in the 
Treaty of Shimonoseki after the First Sino-Japanese War in 1895, and was colonized 
by Japan till the end of the Second World War (1945). In 1945, a civil war broke out in 
China. In 1949, the government of the Republic of China (ROC), defeated by the 
communists, moved to Taiwan; on the mainland, the People’s Republic of China (PRC) 
was established by the victorious communists. In 1950s-1960s, ROC (Taiwan) was the 
representative entity of China in the United Nations. In 1971, PRC (mainland China) 
replaced ROC (Taiwan) as the representative entity of China to the United Nations 
and all organizations related to the United Nations, including WHO.66 Thereafter, 
Taiwan has been isolated from the international community and has had very limited 
opportunity to participate in meetings of WHO and other international activities. 
 
1.6 Structure of tuberculosis services in Taiwan, 1950- 2000 
 
In the era of Japan’s colonial occupation, there were Sungshan Sanatorium in 
northern Taiwan and Chingfeng Sanatorium in southern Taiwan.67  After the Second 
World War, the tuberculosis program was established step by step, beginning with 
the establishment of Taipei Tuberculosis Control Center (the former Sungshan 
Sanatorium) on 1 May 1950; subsequently, Chiayi Tuberculosis Control Center was 
established in 1951 (the former Nanjing Tuberculosis Control center in China was 
moved to Chiayi in 1949), Tainan Tuberculosis Control Center (the former Chingfeng 
Sanatorium) in 1952, and Taichung Tuberculosis Control Center in 1960. These four 
centers formed the backbone of a vertical tuberculosis program over the period 
1950-2000 in Taiwan. The first local Anti-Tuberculosis Association was initiated in 
1951 in Chiayi.67 To strengthen tuberculosis services at district (county/city) level, the 
first district tuberculosis dispensary was set up in 1955; by 1964, a district 
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tuberculosis dispensary has been established in each of the 22 districts (county/city) 
in Taiwan. In 1965, tuberculosis control was listed as the top priority of public health 
(through an official statement of the President of ROC). Consequently, in 1967, the 
four tuberculosis centers were re-structured as Taiwan Provincial Tuberculosis 
Control Bureau (TPTCB) and its three regional branches in Taichung, Chiayi and 
Tainan. A demonstration center was established within TPTCB to guide the policy in 
the diagnosis and treatment of tuberculosis. The district tuberculosis dispensary was 
supported by a health station at each township and village.67 In addition, there were 
2 metropolitan centers, Taipei City and Kaohsiung City, being established at a later 
point in time, in which tuberculosis services were managed by Taipei Municipal 
Chronic Disease Hospital and Kaohsiung Chronic Disease Control Center, respectively. 
The Bureau, 3 regional branches and 2 metropolitan centers formed the structure in 
which tuberculosis services were provided to inhabitants of Taiwan till 2000 (Figure 
2). 
 
 
 
Figure 2. Regions of tuberculosis services in Taiwan, 2000 
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1.7 Burden of tuberculosis in Taiwan  
 
Tuberculosis was an endemic disease in the 1950s in Taiwan. In 1951-1952, a large 
scale tuberculin survey was conducted, in which 5 TU purified protein derivative 
RT-22 tuberculin was used and a positive cut-off was defined as an induration of 5 
mm or greater. The proportion of children 5 years old with a positive reaction was 
15.4%, and that at 10, 15 and 20 years old were 28.1%, 50.7% and 74.8%. (Figure 
3).67  
 
 
Figure 3. Tuberculin survey in Taiwan, 1951-1952: proportion with a positive 
tuberculin skin test (TST), by age and sex  
 
Thereafter, the tuberculin skin test was done among students of the first grade of 
primary school if they had no BCG scar, which provided data on annual risk of 
infection for decades (Figure 2).68 However, BCG was introduced in Taiwan in 1950. 
As the proportion of students of the first grade of primary school without a BCG scar 
decreased from 37% in 1972, to 21.9% in 1980, 6.2% in 1990 and 2.5% in 2000, data 
obtained from this subset of students may not be representative. Before the 
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establishment of a proper surveillance system, tuberculosis mortality and prevalence 
surveys provided a better insight on the trend of tuberculosis in Taiwan.  
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Figure 3. Estimated Annual risk of infection (ARI), Taiwan, 1972-2000 
Note: ARI=1-(1-P)1/n , where p is prevalence of tuberculous infection among children 6 
years old determined by 1 Tuberculin Unit (RT23) and n is age. Data of 1982, and 
1992-1995 were missing and were imputed using a moving average of the previous 
three years 
 
 
1.8 Mortality of tuberculosis in Taiwan 
 
Taiwan established a vital registration system after the Second World War.69, 70 In 
1947, the number of persons who died of tuberculosis was as high as 18,533 persons 
with a tuberculosis mortality rate of 294.4 per 100 000 population (figure 4);67, 71 
tuberculosis accounted for 16.2% of all deaths in Taiwan. Tuberculosis mortality 
decreased substantially to 91.6 per 100 000 population in 1952 (accounting for 9.6% 
of total deaths and ranked 3rd among the leading causes of death), and further went 
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down to 45.7 per 100 000 population in 1960 (5th leading cause of death), 28.4 per 
100 000 population in 1970 (6th leading cause of death), 14.1 per 100 000 population 
in 1980 (9th leading cause of death), 10.7 per 100 000 population in 1985 (first time 
not on the list of top ten leading cause of death in Taiwan), 9.6 per 100 000 in 1990 
(11th leading cause of death), 6.9 per 100 000 population in 2000 (11th leading cause 
of death), and 3.2 per 100 000 in 2009.69, 70  
 
 
Figure 4. Tuberculosis Mortality in Taiwan, 1947 – 2009 
 
Tuberculosis mortality among males has been consistently higher than that among 
females in Taiwan. The male to female tuberculosis mortality ratio was 1.6 in 1952, 
2.5 in 1976, and 3.6 in 2000.68 There was a shift of tuberculosis deaths from the 
youth to the elderly over time (Figure 5). In 1952, a total of 7,262 persons died of 
tuberculosis among whom 31.3% were aged 0-24 years and 9.9% aged 65 years or 
more; in 1976, 3,155 died of tuberculosis among whom 4.7% were aged 0-24 years 
and 39.4% aged 65 years or more; in 2000, 1,534 died of tuberculosis among whom 
0.5% were aged 0-24 years and 78.0% aged 65 years or more.     
 24
 
Figure 5. Tuberculosis Mortality, Taiwan, 1952, 1976 ,2000, by age group 
 
 
1.9 Prevalence of tuberculosis in Taiwan 
 
 
Figure 6. Prevalence of bacteriologically-confirmed pulmonary tuberculosis, Taiwan, 1957-1993 
 
Tuberculosis prevalence surveys have been conducted eight times in Taiwan. The first 
prevalence survey was conducted in 1957 and the prevalence of bacteriologically- 
confirmed pulmonary tuberculosis was 1.02%, which decreased to 0.70% in 1962, 
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0.64% in 1967, 0.41% in 1972, 0.27% in 1977, 0.15% in 1982, 0.11%, and 0.06% in 
1993. (Figure 6)72-79  
 
1.10 BCG vaccination in Taiwan 
 
BCG vaccination was introduced in 1950.67 A laboratory was established in 1952 to 
produce BCG locally and the quality of the BCG laboratory was accredited by WHO in 
March 1953. The BCG strain used in the earlier period was Pasteur 1173 P2, which 
was changed to Tokyo 172 in 1976. In the beginning, the target population for BCG 
vaccination was school children, followed by preschool children, and subsequently 
expanded to infants and the newborn. Between 1950-1975, a total of 15,623,660 
children were vaccinated with BCG, of whom 52.7% were school children, 24.0% 
preschool children, 21.1% infants and 2.2% newborn.67 In the 1990s, the BCG 
coverage rate for infants was 95%. The BCG vaccination program continues up to the 
present time, but re-vaccination of children at 12 years-old was discontinued in July 
1997.79 
 
1.11 Case-finding of tuberculosis in Taiwan  
 
The tools used for examination were bacteriological examinations (sputum smear, 
sputum culture, and laryngeal swab culture) and chest radiography. In 1955, a central 
mycobacteriology laboratory was set up at Taipei Tuberculosis Control Center. 
Subsequently, a mycobacteriology laboratory was established at each tuberculosis 
control center and district Tuberculosis dispensary.67 In 1966, 200 tuberculosis  
workers (expanded to 313 in 1968) were hired and each was assigned to one 
township/village health station to carry out activities of tuberculosis control, 
including identification of individuals with suspected tuberculosis in the community 
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by household visits and sputum smear examination.  
 
 
Figure 8. Radiographic screening and prevalence of tuberculosis among teachers, 
Taiwan, 1956 - 1998 
 
The first mobile radiography unit was procured in 1949; the second unit was donated 
by UNICEF in 1952, and another 3 units by Mutual Security Agency USA in 1953.67 
Thereafter, mobile radiographic screening has been widely used in case-finding of 
tuberculosis through different screening programs, such as township/village 
comprehensive program, community mass radiographic screening , target group 
examination (teachers (Figure 8) 80, institutes, prisons, work places, military 
conscripts, etc), and special projects in aboriginal areas. 81 In the township/village 
comprehensive program, children under 5 years of age were given BCG vaccination 
and those aged 20 years or older had both symptom screening and radiographic 
screening. Such a comprehensive program was mainly conducted in high tuberculosis 
prevalence areas. Screening among teachers was conducted annually from 1956 and 
every 2-3 years from 1966 till the 1990s. Community mobile screening continued up 
to the 1990s, and gradually shifted to high risk group screening (prison and long term 
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care facility).82         
 
1.12 Registration and treatment of tuberculosis in Taiwan 
 
Registration and treatment of tuberculosis started in 1957.82 Initially, only 
bacteriologically-confirmed cases were registered and treated with anti-tuberculosis 
drugs; thereafter, it was expanded to include cavitary pulmonary tuberculosis in 1969, 
cases with extensive parenchymal involvement in 1974, pleural tuberculosis cases in 
1978, pathologically-confirmed extra-pulmonary tuberculosis cases in 1981, 
moderately advanced pulmonary tuberculosis cases in high incidence areas in 1984, 
and minimal pulmonary tuberculosis cases in aboriginal areas in 1988.82 Isoniazid (H) 
alone was used for anti-tuberculosis treatment in 1957. Streptomycin (S) and PAS 
were introduced in 1958; the regimens commonly used were the combination of H 
and S, or of H and PAS. In 1967, thiacetazone(T) was introduced to replace PAS. In 
1974, the standard regimen was H, S, and T for 2 months, followed by H and S twice 
per week for 10 months followed by H daily for 12 months( 2 HST/10H2S2/12H). In 
1977, ethambutol (E) was introduced to replace thiacetazone and patients were 
classified as either new cases or retreatment cases. Regimens for new patients lasted 
for 2 years; initially HSE daily for 3 months, followed by HE for 9 months, and H alone 
for 1 year. Rifampicin (R) and pyrazinamide (Z) were introduced at this time. 
Regimens for retreatment cases were HRE, or HEZ plus cycloserine or 
prothionamide.83 In October 1978, Rifampicin-based regimens were applied in the 
treatment of both new (5HRE/5H) and retreatment cases (2HRE/8H2 R2E2).67 
Treatment was mainly supervised by public health workers but directly observed 
therapy was not in place. In 1978-1980, of the 12,533 new patients treated with 
(5HRE/5H), 79.8% were successfully treated and 14.3% lost to follow-up; the 
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respective figure for 1,805 retreatment cases was 69.9% and 20.9%.84 In 1990, 
6-month Short-course chemotherapy (2HRZE/4HRE) was applied, and in 1993, fixed 
dose combinations were introduced. 
 
Contact examination was done in the 1970s. Isoniazid preventive therapy for 6 
months was offered to children <15 years old who were tuberculin skin test positive 
(induration of 10 mm among those without a BCG scar and 20 mm among those 
with).83  
 
1.13 From prevalence survey to surveillance of tuberculosis 
 
Registration of tuberculosis cases in the earlier period was incomplete and did not 
accurately reflect the epidemic of tuberculosis in Taiwan. Poverty, poor access to care, 
and insufficient capacity of tuberculosis services resulted in under-detection of 
tuberculosis cases. Economic development in Taiwan saw the improvement in quality, 
capacity, accessibility and affordability of the health care system. Increasing numbers 
of tuberculosis patients were treated outside the vertical tuberculosis system 
through different insurance programs. To strengthen surveillance of tuberculosis, all 
reported tuberculosis cases were registered since 1st September 1991, and 
notification of extrapulmonary tuberculosis became mandatory since 1st March 
1997.79   
 
To improve the completeness of reporting, various efforts have been made, including 
issuing administrative orders, promoting notification of tuberculosis in official 
meetings and scientific conferences, and revising the reporting form to facilitate 
reporting of extra-pulmonary tuberculosis. All these efforts contributed to increased 
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tuberculosis reporting. However, the overall picture of tuberculosis case finding and 
reporting changed considerably after the implementation of the national health 
insurance program. 
 
1.14 National Health Insurance in Taiwan 
 
Since the 1950s, several health insurance programs have been established in Taiwan. 
The top three programs were Labor Insurance, Government Employee Insurance, and 
Farmer's Health Insurance, which covered approximately 55% of the total 
population.85, 86 Those who were not covered by any insurance program were 
children <15 years old, the elderly aged 65 years or more and those who had no 
regular job. Acting on the National Health Insurance (NHI) Law passed by the 
Legislative Yuan (Parliament) in 1994, the Department of Health set up the Bureau of 
National Health Insurance to implement the NHI Program in Taiwan. The NHI 
Program was a single payer health insurance system operated by the government 
under the principle of mandatory and universal enrollment. The proportion of the 
population insured under the NHI Program was initially 92% when it was launched in 
March 1995, quickly reached 96% by December 1996, and has been around 99% till 
the present time.86, 87 With the implementation of the NHI program, most hospitals 
and clinics (more than 90%) have signed contracts with the Bureau of NHI, and 
fee-for-service claim payments are reimbursed by the Bureau of NHI on a monthly 
schedule.  
 
The health care system in Taiwan is a market-oriented system regulated by the laws 
of supply and demand; health providers (clinicians) are free to set up their practice 
and patients are free to seek health services from any clinician. A referral system was 
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established but tiered referral procedures were not mandatory; patients who prefer 
to visit tertiary care hospitals can do so without any referral even for simple illnesses 
such as upper respiratory infection.85, 86, 88, 89 The establishment of the NHI program 
fundamentally changed the landscape of tuberculosis services in Taiwan. NHI 
program facilitated accessibility and affordability of health services among those who 
need it most, especially the elderly aged 65 years or more, who accounted for 42% of 
reported tuberculosis cases in 199779 and 49.6% in 2009.90 Because tuberculosis 
patients can receive treatment for tuberculosis in any health care facility under the 
coverage of NHI program, and because county hospitals, regional hospitals and 
tertiary care hospitals were equipped with advanced medical technology and staffed 
with well trained medical personnel that usually outperformed the vertical 
tuberculosis program, tuberculosis patients may not be willing to be referred to the 
vertical tuberculosis program for further management . General health care facilities 
may be reluctant to refer tuberculosis patients to the official tuberculosis control 
system because reimbursement from the NHI program was based on a fee-for-service 
mechanism. As a result, the number of tuberculosis patients receiving 
anti-tuberculosis treatment at general health care facilities increased continuously 
over time and eventually outnumbered those treated in the vertical tuberculosis 
control system .82 
 
1.15 Strengthening surveillance of tuberculosis through NHI 
 
After the implementation of the NHI program, NTP took advantage of the NHI 
program to further strengthen notification of tuberculosis. NTP worked with the 
Bureau of NHI to introduce the no-notification-no-reimbursement (NNNR) policy and 
the notification-fee (NF) policy.91 The NNNR policy, stating that notification of 
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tuberculosis is a requirement for reimbursement, was announced in May 1997 and 
implemented from July 1997. The NF policy, stating that 250 New Taiwan dollars 
(USD$ 8) for each confirmed tuberculosis case would be given to reporting 
clinicians/hospitals, was implemented from October 1997. The announcement of the 
NNNR policy in May 1997 coincided with a prompt increase in reported cases in the 
second quarter of 1997. Upon the implementation of the NNNR policy, reported 
cases reached a historic peak in the third quarter of 1997. In 1997, there were a total 
of 15,386 incident tuberculosis cases, with a notification rate of 71.1 per 100,000.  
 
 
Figure 9. Source of registered tuberculosis cases in Taiwan, 1991-2000 
 
The increase in reported cases has been primarily due to improvements in 
notification, especially from general hospitals/clinics, rather than to a resurgence of 
tuberculosis in Taiwan. The increase in numbers of cases reported from general 
hospitals/clinics reflected an immediate impact of the NHI policies on tuberculosis 
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notification, with no increase in reported cases within the official TB system. In the 
early 1990s, around 50% of tuberculosis cases were registered through the official 
tuberculosis system, which decreased to less than 20% in the year 2000; in contrast, 
around 30% of tuberculosis cases were reported by general hospitals/clinics in early 
1990s, which increased to about 80% in the year 2000 (figure9).90 Thereafter, 
notification of tuberculosis became a better tool than before in monitoring the 
epidemic of tuberculosis in Taiwan.       
 
1.16 Time for a change 
 
Tuberculosis services in Taiwan in the 1950s-1970s were in line with WHO policies. In 
1980s, while Taiwan shared the spirit of the Alma Ata Declaration42 and took action 
to strengthen the primary health care system, integration of managerial functions of 
tuberculosis services did not take place and the vertical tuberculosis program 
continued operation in Taiwan. In 1989, the Tuberculosis Control Bureau was 
renamed the Chronic Disease Control Bureau (CDCB), and the district (county) 
tuberculosis control dispensary was renamed the county chronic disease control 
dispensary, with its function expanded to include screening and health education of 
diabetes and hypertension. While there was no disruption of tuberculosis services in 
the 1980s in Taiwan, it has been increasingly difficult to efficiently operate a vertical 
tuberculosis program in an evolving health care system, especially after the 
implementation of the national health insurance program. As the majority of 
tuberculosis patients were diagnosed and treated outside the vertical program 
through national health insurance, patients who were referred to the vertical 
program decreased to a minority, mainly those who did not participate in the NHI 
program, those with major adverse reactions, those who were difficult to treat and 
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those who had drug-resistant tuberculosis. The evolving health care environment 
imposed several challenges on the vertical program.  
 
First, the quality of the diagnosis and treatment of tuberculosis in the general health 
care system was difficult to ensure. Information on reported tuberculosis cases 
provided by general health care facilities was incomplete and difficult to obtain. 
Sputum examination was frequently not done and the proportion of 
bacteriologically-confirmed pulmonary tuberculosis cases among notified pulmonary 
tuberculosis cases was low (36.3% in 199982). However, CDCB and its regional 
branches had limited budget for program operation and insufficient administrative 
authority in dealing with the health care system. CDCB was administratively under 
the Provincial Department of Health, at the same level of Provincial hospitals. 
 
Second, life expectancy at birth of males increased from 59.6 years in 1955 to 72.7 
years in 2000, and that for females from 62.8 years to 78.4 years.92 The top 5 leading 
causes of death were gastro-intestinal diseases, pneumonia, tuberculosis, heart 
disease and cerebrovascular diseases in 1952, but have changed to malignant 
neoplasms, cerebrovascular diseases, heart diseases, accidents, and diabetes mellitus 
in the year 2000. Health authorities did not give priority to tuberculosis. Integration 
of tasks (expanded program on immunization, maternal and child health, 
non-communicable diseases, etc) of public health nurses at township/village health 
stations took place in the 1980s. Tuberculosis workers formerly enrolled under the 
vertical tuberculosis program were tasked with additional duties and shared 
tuberculosis-related activities with other public health nurses. Consequently, 
tuberculosis was easily neglected and case-holding was getting difficult to organize, 
especially for tuberculosis patients treated in the general health care system. The 
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proportion of tuberculosis patients with successful treatment was 77.1% among 
patients notified in 1996, 78.4% in 1997, 75.1% in 1998, 76.6% in 1999, and 74.2% in 
2000; the respective proportion of patients who were lost to follow-up was 11.3%, 
8.9%, 8.1%, 6.6%, and 7.0%.68, 71, 79, 82, 93 Interruption of treatment was particularly a 
problem in the treatment of multidrug-resistant tuberculosis and the proportion who 
interrupted treatment for 2 months or more was as high as 29% for the cohort 
treated in 1992-1996.14 
 
In addition, the construction of CDCB was built on the property of National Taiwan 
University, who planned to use the land to build a new Children’s Hospital and had 
been requesting return of the land for years. CDCB had land of its own, which was 
occupied by another institute. The Provincial government remained indecisive for 
years concerning whether to construct a new building for CDCB. Eventually, CDCB 
temporarily rented a building in Taipei County and moved there in January 1998. 
Staff of CDCB was heavily demoralized and many of them left the program.  
 
1.17 Integration of tuberculosis services, 2001 
 
Taiwan Centers for Disease Control (CDC), Department of Health, was established in 
the year 2000. Taiwan CDC as part of central government enjoys a much higher level 
of administrative authority than CDCB. Since the mandate of Taiwan CDC is to control 
communicable diseases, integration of tuberculosis control into Taiwan CDC had 
been an issue for elaboration. The official tuberculosis control system was considered 
to have two distinct but inter-related functions: 1) clinical services including diagnosis 
and treatment of tuberculosis, and 2) public health function, including policy, 
planning, case finding, surveillance, advocacy, health education, prevention, case 
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holding, contact tracing, recording and reporting. CDCB had a hospital with 100 bed 
capacity and staffed with several well trained medical doctors (the majority were 
qualified internists and pulmonologists) who not only participated in the 
implementation of the tuberculosis program but also provided medical care services, 
especially for drug-resistant tuberculosis and difficult-to-treat tuberculosis. As 
second-line anti-tuberculosis drugs were not available at most general health care 
facilities, the majority of multidrug-resistant tuberculosis patients were referred to 
CDCB and its three regional branches for management.  
 
Different options of integration of tuberculosis program into Taiwan CDC were 
elaborated. Eventually, it was decided that Taiwan CDC would take over the public 
health function but not the clinical function of CDCB. Most clinicians of CDCB and its 
regional branches left the program to work in general hospitals. Drastic re-structuring 
from a vertical tuberculosis program to a fully integrated approach started in July 
2001 when Taiwan CDC formally took over the National Tuberculosis Program and 
was completed when the clinical functions of CDCB in Taipei were closed in August 
2002.  
 
1.18 Challenges of tuberculosis services after integration, 2002 onward 
 
Under the vertical tuberculosis program, there were medical officers and senior 
public health nurses assigned to each county/city as supervisors. The records of 
reported tuberculosis cases were reviewed by medical officers to verify the accuracy 
of case notifications (whether or not they fitted the definition for tuberculosis). 
Medical officers also offered advice when clinicians of general health care facilities 
had difficulty in deciding whether anti-tuberculosis treatment was required. Senior 
 36
public health nurses supervised tuberculosis case management, as well as recording 
and reporting. In the 1990s, it was already noticed that chest radiography 
examinations were heavily used, overdiagnosis and misdiagnosis of tuberculosis 
were not infrequent, and bacteriologically examinations were neglected. 
Strengthening mycobacteriology laboratory services has been listed as an urgent 
issue by the former CDCB.93 After Taiwan CDC took over NTP in 2001, most medical 
officers and senior public health nurses were not recruited in Taiwan CDC. A 
quality-assured laboratory system was not in place. New mechanisms of supervision 
and monitoring were not established. Completeness and accuracy of notification 
data were not ascertained. Diagnosis and treatment of tuberculosis were left to all 
clinicians in general clinics/hospitals, under a naïve assumption that all clinicians 
know how to diagnose and treat tuberculosis. 
 
Taiwan CDC promoted the concept that according to the communicable disease 
control law, not only confirmed tuberculosis cases must be reported but also 
individuals with suspected tuberculosis. Subsequently, notification of tuberculosis 
increased. However, inexperienced clinicians at general health care facilities had no 
regular channel of consultation for the diagnosis and treatment of tuberculosis. 
Many patients who were not treated with anti-tuberculosis drugs were notified to 
health authorities and Taiwan CDC. A substantial number of notified patients, who 
were either treated or not treated with anti-tuberculosis drugs, had their diagnosis 
of tuberculosis changed. In 2003, a total of 22,362 suspected and confirmed 
tuberculosis cases were notified, of which 6,612 (29.6%) had their diagnosis changed 
and were thus regarded as ‘non-notifiable’.94  
 
Clearly, several challenges related to laboratory services, diagnosis, treatment, case 
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management, and surveillance of tuberculosis emerged after re-structuring. 
Constraints of tuberculosis services that emerged following the integration of vertical 
tuberculosis program into general health care system need to be identified and 
addressed to ensure efficiency and effectiveness of the new approach. Questions 
included: 
1. Was the quality of smear microscopy satisfactory? 
2. Were all culture positive patients treated with anti-tuberculosis drugs? 
3. Were tuberculosis patients advised to stop anti-tuberculosis treatment before 
completing a treatment course and what were its associated factors? 
4. Were prescribing practices for anti-tuberculosis drugs in the treatment of 
tuberculosis adequate? 
5. What were the proportions of patients who had treatment interruption and 
died during anti-tuberculosis treatment and their associated factors? 
6. Was the classification of notified tuberculosis cases accurate?  
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2. Study aims 
 
2.1 Broad Objective 
 
To assess tuberculosis services and surveillance after the integration of the vertical 
tuberculosis program into general health care system in 2001. 
 
2.2 Specific Objectives 
 
1. To evaluate quality of smear microscopy of 4 mycobacteriology laboratories 
who provided slides for a training course in 2004. (Paper 1) 
2. To assess tuberculosis-related deaths without treatment in Taipei in 2003. 
(Paper 2) 
3. To investigate factors associated with a clinician's decision to stop 
anti-tuberculosis treatment before completion in Taipei in 2003. (Paper 3) 
4. To evaluate prescribing practices for anti-tuberculosis drugs in the treatment 
of tuberculosis in Taipei in 2003. (Paper 4) 
5. To investigate outcome of tuberculosis and factors associated with treatment 
interruption and death in Taipei in 2003. (Paper 5) 
6. To assess accuracy in the classification of notified tuberculosis cases in Taipei 
in 2003. (Paper 6) 
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3. Methods 
 
Table 1 shows outcome, determinants and analytic approaches of papers 1-6. Figure 
10 shows study population of papers 2-6. 
 
Table 1. Outcome, determinants and analysis of original papers 
Paper Outcome Determinants Analysis 
1 1. Smear with proper 
size, thickness and 
staining. 
2. Major and minor 
errors per laboratory 
 
None 1. Descriptive 
analysis that 
presents 
numbers and 
proportions 
2 1. Failure to initiate 
anti-tuberculosis 
treatment in 
reporting health 
facilities 
Sex, age, sputum 
smear, type of case, 
concomitant diseases 
(pneumonia, 
sepsis/respiratory 
failure, cardiovascular 
disease, hepatic 
disease, and cancer) 
 
1. Pearson’s chi 
square test, 
2. Fisher’s exact test 
3. Multivariable 
logistic regression 
analysis 
3 1. Starting anti- 
tuberculosis 
treatment on the 
basis of each type of 
clinical investigation 
2. Decision to stop 
anti-tuberculosis 
treatment before 
completion (change 
diagnosis) 
 
Sex, age, type of 
reporting facilities, 
cancer, treatment 
interruption for 2 
consecutive months, 
transferred  
1. Pearson’s chi 
square test, 
2. Multivariable 
logistic regression 
analysis 
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Table 1. Outcome, determinants and analysis of original papers (continued) 
Paper Outcome Determinants Analysis 
4 1. Frequency of correct 
dosage, lower than 
recommended dosage 
and higher than 
recommended dosage 
of each drug 
 
Sex, age, body 
weight, type of case, 
sputum smear, liver 
disease, renal disease 
1. Pearson’s chi 
square test. 
 Multinomial 
logistic regression 
models
5 1. Outcome of 
treatment (treatment 
success, died, failed, 
treatment 
interruption/ still on 
treatment, 
transferred out),  
2. Excess mortality 
3. 1-year mortality 
Sex, age, sputum 
smear, sputum 
culture, TB treatment 
history, visited other 
health facilities, 
concomitant diseases, 
Diabetes, respiratory 
disease, 
cardiovascular 
disease, infectious 
disease, cancer, renal 
disease, hepatic 
disease   
 
1. Pearson’s chi 
square test  
2. Standardized 
mortality ratio 
3. Kaplan-Meier 
survival 
estimates, 
4. Log rank test 
5. Cox proportional 
hazards model 
6 Official classification of 
reported tuberculosis 
cases by type of case, with 
specific interest on 
proportion of not-a-case 
classified as new TB case, 
definite cases classified as 
not-notifiable, and 
untreated individuals with 
suspected TB classified as 
new cases 
None 1. Descriptive 
analysis that 
presents 
numbers and 
proportions 
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Tuberculosis cases notified to Taiwan CDC, N= 22362 cases 
Residents of Taipei City, N=2096 
Citizen of Taiwan, N=2018 
Case records located and reviewed: 1973 (97.8%)  
 (study population of paper 6) 
Treated, N=1716 (87.0%) 
(study population of paper 4) 
Culture-positive for M. 
tuberculosis, N=536 (27.2%) 
(study population of paper 2)
Rest of Taiwan, N=20266 
Foreigners, N=78 
Case records not reviewed, N=45 
Not treated, N= 257 
Culture positive but species 
identification not done, 
N=199; Nontuberculous 
mycobacterium, N=167; 
Smear positive but culture 
negative or unknown, N= 47; 
bacteriologically unconfirmed, 
N=1024. 
Extrapulmonary disease, N=312  
Pulmonary Tuberculosis, N=1661 
Not treated, N=229 
Treated, N=1432(86.2%)
Extra-pulmonary TB, N=99 
Pulmonary tuberculosis, N=1333 
Previously treated, N=109 
New cases, N= 1224 (91.8%)  
(study population of paper 3) 
Nontuberculous 
Mycobacterium, N=121  
M. tuberculosis, N=1311 (84.2%) 
Diagnosis changed, N=184 
Pulmonary TB, N= 1127(86.0%) 
(study population of paper 5) 
Figure 10. Flow chart of study population of papers 2-6 
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3.1 Quality of sputum smear microscopy in Taiwan. (Paper 1)  
 
Four sets of slides collected from routine services at four mycobacteriology 
laboratories for a training course on quality assurance of smear microscopy were 
used for this study.95 Participants of the training course used a systematic sampling 
method to choose 100 to 120 slides from a set of 600 to 800 slides for evaluation. 
Participants judged the size, thickness, and staining (de-staining) of smears as G 
(good or acceptable) or P (poor), and re-checked slides blinded to the microscopy 
results reported by the testing laboratories. Discordant slides were re-examined by a 
second re-checker in order to make the final decision. The internationally- 
recommended classification of errors was used.96 High false positive and high false 
negative results were classified as major errors, while low false positive, low false 
negative, and quantification errors were considered to be minor errors. Outcome 
assessed were the proportion of slides with proper size, thickness and staining as 
well as the number and proportion of both major and minor errors per laboratory. 
No determinant associated with outcome was analyzed because the number of 
laboratories was small. Analysis was descriptive that present number and proportion 
of relevant outcome. Data reported by course participants were validated by course 
facilitators.  
 
3.2  Study population and data management of papers 2-6. 
 
Study population of papers 2-6 came from a cohort of suspected and confirmed 
tuberculosis cases whose official residence was Taipei City notified to health 
authorities in 2003 (2003 Taipei Cohort, Figure 10). Characteristics of these notified 
cases were investigated by review of their medical charts at the reporting health 
facilities. An official document was issued from Taiwan CDC to all health facilities to 
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obtain approval for carrying out the review. None of the reporting facilities refused 
to give approval. A structured questionnaire was designed and pilot tested. A team 
of 22 persons was organized and trained for data collection. Data were entered into 
the computer using EpiData 3.1 (The EpiData Association, Odense, Denmark). The 
complete data set was re-entered by a different person. Validation of the two 
computerized data sets was carried out using Epidata 3.1. Discrepant records were 
checked and corrected according to the original data on the questionnaires. STATA 
Version 8.0 (STATA Corporation, Houston, TX, USA) was used for statistical analysis. 
 
3.3 Tuberculosis-related deaths without treatment. (Paper 2) 
 
Tuberculosis cases that were culture positive for M. tuberculosis of the 2003 Taipei 
cohort were included in this study. Cases were classified as treated or not treated 
with anti-tuberculosis drugs after review of their case records. Outcome of interest 
was failure of initiation of anti-tuberculosis treatment for culture-positive TB patients 
in reporting health facilities. Determinants were sex, age, sputum smear, type of case, 
concomitant diseases (pneumonia, sepsis/respiratory failure, cardiovascular disease, 
hepatic disease, and cancer). A multivariable logistic regression model was 
constructed to assess factors associated with no treatment.  
 
3.4 Factors associated with a clinician's decision to stop anti-tuberculosis treatment 
before completion. (Paper 3) 
 
Newly diagnosed pulmonary tuberculosis cases from the 2003 Taipei cohort who did 
not have concomitant extra-pulmonary disease and who had not previously been 
treated for tuberculosis were included in this study. The procedure of clinical 
investigation leading to a decision to start treatment for pulmonary tuberculosis was 
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classified as follows: 
1. Chest radiograph (CXR): immediate start of treatment after CXR, based solely 
on CXR findings. 
2. Smear: start of treatment after CXR and a positive AFB smear. 
3. Other: start of treatment after further investigations (such as bronchoscopy, 
pathology and polymerase chain reaction), but before culture result. Sputum 
AFB smear was negative or not done/ reported. 
4. Culture: start of treatment after positive sputum culture. 
 
Cases were classified by bacteriological status, as follows: 
1. ‘Definite’ cases: presence of M. tuberculosis confirmed by culture. 
2. ‘Other confirmed’ cases: Mycobacterium isolated but species determination 
not performed, and sputum smear-positive for AFB but culture not 
performed. 
3. ‘Not a case’: only environmental mycobacteria isolated on culture. 
4. ‘Indeterminate’: all other cases, including smear-positive, culture-negative 
cases. 
5. Bacteriologically-confirmed cases: definite cases and other confirmed cases. 
 
The proportion of patients starting anti-tuberculosis treatment according to each 
type of clinical investigation was assessed. Univariate analysis of factors associated 
with basis for diagnosis was done by chi square test and multivariate analysis by 
logistic regression. The proportion of patients who had their diagnosis of TB changed 
by a clinician and anti-tuberculosis treatment discontinued before completion was 
assessed. Factors associated with clinician’s decision to stop anti-tuberculosis 
treatment before treatment completion (changed diagnosis) were analyzed by chi 
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square test and multivariate logistic regression. 
 
3.5 Inconsistent dosing of anti-tuberculosis drugs in Taipei. (Paper 4) 
 
The full 2003 Taipei cohort was included in this study. A medical audit of patients’ 
medical charts was performed to collect pretreatment body weights and regimens 
prescribed at commencement of TB treatment. The dosages prescribed were then 
compared with recommended dosages. Outcomes were correct dosage, lower than 
recommended dosage and higher than recommended dosage of each drug. 
Categorical variables were analysed using Pearson’s chi square test. P < 0.05 was 
considered statistically significant. Significant determinants were entered into 
multinomial logistic regression models in which the outcome variable had three 
categories (correct dosage, lower than recommended dosage and higher than 
recommended dosage) and a final fitted model was determined by backward 
elimination using the likelihood ratio test. 
 
3.6 Tuberculosis outcomes in Taipei: factors associated with treatment interruption 
for 2 months and death. (Paper 5) 
 
Pulmonary tuberculosis cases of the 2003 Taipei cohort who were treated with 
anti-tuberculosis drugs were included in this study. Treatment outcome was 
classified using the following definitions: 
1. Treatment success: cured, for patients who were sputum culture-negative for 
M. tuberculosis at the last month of treatment and on at least one previous 
occasion, or treatment completed, for patients who had completed treatment 
but who did not meet the criteria to be classified as cured or failed. 
2. Failed: patients who remained or became again sputum culture-positive for M. 
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tuberculosis at 5 months or later during treatment. 
3. Died: patients who died for any reason during the course of treatment. 
4. Defaulted: patients who either 1) interrupted treatment for at least 2 
consecutive months (interrupts) or 2) were still on treatment 15 months after 
commencing anti-tuberculosis treatment (remained on treatment). 
5. Transferred out: patients who had been transferred to another 
recording/reporting unit and for whom the treatment outcome was not 
known. 
 
To assess the risk of death, all patients were followed up from the time of effective 
treatment until death or last contact. Cases with a follow-up of စ1 year were 
censored at 1 year. Excess mortality of TB patients was determined by comparison 
with national mortality rates in 2003 published by the Department of Health. 
Kaplan-Meier survival estimates and log rank test were used to evaluate factors 
associated with death. All significant variables were entered into a multivariate Cox 
proportional hazards model, and a final fitted model was determined by backward 
elimination using the likelihood ratio test. The final model was checked by 
diagnostics including link test, graphical methods and residual analysis. 
 
3.7 Accuracy of classification of notified tuberculosis cases in Taiwan (Paper 6) 
 
All suspected and confirmed tuberculosis cases notified to health authorities in 
Taiwan in 2003 were identified from the national tuberculosis registry at Taiwan CDC. 
Reported cases of Taipei city was compared with those of rest of Taiwan. The full 
2003 Taipei cohort were investigated by review of their medical charts at the 
reporting health facilities. Classification of reported cases by Taiwan CDC (Died 
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before registration, Treatment completed before registration, Diagnosis changed by 
physician, Non-notifiable (administrative coding), Newly-diagnosed case) were 
cross-tabulated with type of cases defined above (definite cases, other confirmed 
cases, indeterminate, and not-a-case) to assess accuracy in the classification of 
notified cases. 
 
Ethics approval 
Study 1 used data collected in a training course on quality of smear microscopy and 
did not access any individual information on patients; therefore, ethics approval was 
waived. Papers 2-6 reviewed medical charts and did not involve any patient 
interviews; these studies were approved by the Review Board of Taiwan CDC and 
funded by Taiwan CDC. An official document was issued by Taiwan CDC to all health 
facilities that reported TB cases to obtain approval for review of patient records; all 
of the reporting facilities gave approval. 
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4. Synopses of papers 
 
4.1 Quality of sputum smear microscopy in Taiwan (paper 1) 
 
The Eastern Region of the International Union Against Tuberculosis and Lung Disease 
(The Union) organized an international training course on quality assurance of 
sputum smear microscopy for tuberculosis control in Taipei from 19 to 27 August 
2004.95 Four mycobacteriology laboratories in the northern part of Taiwan collected 
slides from their routine work of sputum smear microscopy for the training course. 
Three laboratories provided a set of 600 slides and the fourth a set of 800 slides. This 
provided an opportunity to evaluate the quality of sputum smear microscopy in the 
collaborating laboratories.  
 
A total of 433 slides were evaluated for their quality. The size of the smear prepared 
in one laboratory was uniformly judged to be too small. A substantial proportion of 
slides had at least a part of the smear sloughed off. Some slides had poor smearing, 
some smears were uneven, some too thin, some too large, and some incompletely 
decolorized. Of the 433 slides, 177 (41%) had proper size of smear, 194 (45%) proper 
thickness and 212 (49%) proper staining. Re-checking of the 433 smears (220 
non-re-stained and 213 re-stained) by participants revealed seven as high false 
positive. These had to be excluded from the analysis because of the sloughing-off of 
the smears. Two of the 4 laboratories had at least one high false negative and 3 
laboratories had at least one low false negative result.  
 
We concluded that 1) the 2 laboratories with high false negative results needed a 
supervisory visit to determine the causes and 2) the National Tuberculosis Program 
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should pay due attention to the quality of sputum smear microscopy and develop a 
formal plan for external quality assessment of sputum smear microscopy in Taiwan. 
 
4.2 Tuberculosis-related deaths without treatment (paper 2) 
 
In 2003, 2,018 citizens of Taipei City diagnosed with tuberculosis were notified. To 
investigate tuberculosis patients who died without anti-tuberculosis treatment, the 
case records of 1,973 (97.8%) patients were located and reviewed, of whom 536 
(27.2%) were culture-positive for M. tuberculosis. Of the 536 patients, 507 (94.6%) 
were treated with anti-tuberculosis drugs in reporting health facilities and 29 (5.4%) 
were not. Out of these 29 patients, 26 (89.7%) died, 2 (6.9%) were re-notified at a 
later point in time (one at month 13 after culture examination and another at month 
18) and 1 (3.5%) was lost to follow-up. Of the 26 patients who died, 18 (69.2%) died 
within 1 month of culture examination. Among those 507 patients who were treated, 
71 (14.0%) died during anti-tuberculosis treatment. Overall, of the 536 tuberculosis 
patients who were culture-positive for M. tuberculosis, 97 (18.1%) died, of whom 26 
(26.8%) died without anti-tuberculosis treatment. In multivariable regression analysis, 
patients aged 65 years or more, patients with negative smears or smears not done, 
sepsis and/or respiratory failure and liver disease were significantly less likely to 
receive anti-tuberculosis treatment as compared with other groups. 
 
This study probably underestimated the magnitude of tuberculosis deaths without 
treatment, as autopsies were rarely performed and those who did not undergo 
sputum examination would not be included.  
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4.3 Factors associated with a clinician's decision to stop anti-tuberculosis treatment 
before completion. (Paper 3) 
 
Notification of tuberculosis is mandatory in Taiwan. Reported tuberculosis cases are 
classified as non-notifiable if the reporting clinician changes the diagnosis of 
tuberculosis and reports a decision to stop anti-tuberculosis treatment before 
completion of a full course of treatment. We conducted a study to investigate 
clinicians’ practice in diagnosing pulmonary tuberculosis and to determine factors 
associated with a clinician’s decision to stop anti-tuberculosis treatment before 
completion of a full course (change of diagnosis) in Taipei City.  
 
Of 1,126 pulmonary tuberculosis patients who were treated with anti-tuberculosis 
drugs, 512 (45.5%) started treatment immediately based solely on CXR findings; 
treatment for 214 (19.0%) was based on a positive sputum smear for acid-fast bacilli, 
for 261 (23.2%) on other findings and for 139 (12.3%) on a positive mycobacterial 
culture. Of the 1,126 pulmonary tuberculosis patients, 156 (13.9%) had their 
diagnosis of tuberculosis changed by a clinician. The proportion of cases with a 
changed diagnosis was significantly different between groups of patients according to 
their basis for diagnosis; it was highest among those treated based on “other” 
findings (20.7%) followed by those based on CXR findings (14.8%), positive culture 
(7.9%) and positive smear (7.0%). Multivariate analysis showed that patients whose 
diagnosis was based on CXR or other findings, female patients, patients who 
interrupted treatment for at least 2 months, patients who continued care at other 
health facilities (transferred) and patients with lung cancer were significantly more 
likely to have their diagnosis changed than other groups.  
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Among the various categories of patients, indeterminate cases were most likely to 
have their diagnosis changed (24.4%), followed by patients who were smear-positive 
but culture not done (7.7%), culture positive but species not identified (5.9%) and 
definite cases (3.3%). Of the 156 patients with a change of diagnosis, 83 (52.5%) had 
their diagnosis changed by the reporting facility and 73 (46.8%) by other facilities. 
“Definite cases” were most likely to have their diagnosis changed by other facilities 
(84.6%). We concluded that a substantial proportion of patients were prescribed 
anti-tuberculosis treatment based on CXR findings alone, and a considerable 
proportion of them were advised to stop treatment before completing a full course, 
findings that require the immediate attention of Taiwan’s National Tuberculosis 
Program. 
 
4.4 Inconsistent dosing of anti-tuberculosis drugs in Taipei. (Paper 4) 
 
We investigated prescribing practice of anti-tuberculosis treatment in Taipei. A total 
of 24 different anti-tuberculosis regimens were prescribed for the treatment of 
tuberculosis in 1,700 reported tuberculosis patients aged 15 years or more. Of 1,700 
patients, 1,096 (64.5%) had their body weight recorded. Of 506 patients prescribed a 
three-drug fixed-dose combination (FDC), the dosage was adequate in 374 (73.9%), 
too low in 100 (19.8%) and too high in 32 (6.3%). Patients with a positive smear were 
significantly less likely to be prescribed a lower-than-recommended dose of 3-drug 
FDC (relative risk ratio [rrr] 0.5, 95% confidence interval[CI] 0.3-0.8); patients 
weighing 50 kg or more were significantly less likely to be prescribed a higher-than- 
recommended dose (rrr 0.01, 95%CI 0.001-0.08); and patients with liver disease 
co-morbidity were significantly more likely to be prescribed a lower-than- 
recommended dose (rrr 3.7, 95%CI 1.3-10.6). 
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Of 75 patients prescribed a two-drug FDC, the dosage was adequate in 57 (76.0%), 
too low in 15 (20.0%) and too high in 3 (4.0%). Of 481 patients prescribed rifampicin, 
the dosage was adequate in 302 (62.8%), too low in 152 (31.6%) and too high in 27 
(5.6%). Patients weighing ʁ50 kg were more likely to be prescribed a lower-than- 
recommended dose of rifampicin (rrr 3.7, 95% CI 2.0-6.7) and were less likely to be 
prescribed a higher-than-recommended dose (rrr 0.03, 95% CI 0.01-0.14); patients 
with co-morbidity with renal disease were significantly more likely to be prescribed a 
lower-than-recommended dose of rifampicin (rrr 2.6, 95% CI 1.5-4.7). Of 451 patients 
prescribed isoniazid in single drug preparation, the dosage was adequate in 396 
(87.8%), too low in 29 (6.4%) and too high in 26 (5.8%). 
 
We concluded that the prescribing practices for anti-tuberculosis drugs were 
substandard and needed improvement. 
 
4.5 Tuberculosis outcomes in Taipei: factors associated with treatment interruption 
for 2 months and death (paper 5) 
 
Outcomes of anti-tuberculosis treatment in Taiwan were generally determined 18 
months after the close of the year in which these cases were registered. Classification 
of treatment outcome in Taiwan did not fully follow international recommendations. 
Those who remained on treatment when outcome analysis was carried out were 
classified together patients lost to follow-up (defaulters), but patients who 
interrupted treatment for at least 2 consecutive months (international definition of 
default) were not reported as such. The Taiwan CDC reported the outcomes of 1,278 
tuberculosis cases notified in Taipei in 2003 as follows: 81.3% treatment success, 
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17.0% died, 0.2% failed, 0 defaulted and 0.6% transferred out.  
 
We assessed outcome of 1,127 pulmonary tuberculosis patients and investigated risk 
factors associated with treatment interruption for 2 consecutive months or more and 
death. Treatment outcomes were as follows: 73.1% treatment success, 16.8% died, 
2.8% failed, 5.8% interrupted treatment for at least 2 months and 1.5% were still on 
treatment 15 months after commencing treatment. Treatment outcome was 
significantly associated with age group, sputum smear status, sputum culture status, 
visiting other health facilities during treatment and concomitant diseases. Of the 65 
patients who interrupted treatment for at least 2 months, seven (10.8%) did so 
within 1 month after treatment initiation, 17 (26.2%) between 1 and 3 months. No 
factor was identified to be associated with treatment interruption for at least 2 
months except visiting other health facilities during treatment. 
 
Of the 189 patients who died, 72 (38.1%) died within 1 month of treatment, 69 
(36.5%) between 1 and 3 months. Tuberculosis patients had a standardized mortality 
ratio of 8.7 (95%CI 7.5–10.0). In multivariate analysis, factors significantly associated 
with death were age (adjusted hazard ratio [adjHR] 1.06. 95%CI 1.05–1.08), sputum 
culture not performed / unknown (adjHR 2.07, 95%CI 1.47–2.92), and co-morbidity 
with respiratory disease (adjHR 1.68, 95%CI 1.24–2.27), infectious disease (adjHR 
2.80, 95%CI 2.07–3.78), renal disease (adjHR 2.58, 95%CI 1.82–3.66) or cancer (adjHR 
3.31, 95%CI 2.35– 4.65), as compared with other patients. 
 
In contrast with official reports of no treatment interruption, 5.8% (95% CI 4.4–7.1) 
of patients interrupted treatment for 2 months or more. A high proportion of deaths 
was due to old age and co-morbidity. 
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4.6 Accuracy of classification of notified tuberculosis cases in Taiwan (Paper 6) 
 
We conducted the study to address the following question: ‘How accurate (logically 
consistent) is the classification of cases among Taiwan-born individuals resident in 
Taipei City who were reported to the National Tuberculosis Register? The ‘null 
hypothesis’ tested was: there is more than 95% concordance of classification of 
cases notified as compared with classification derived from logical consistency. 
 
Of 1,973 patients evaluated, 782 (39.6%) were bacteriologically confirmed, 1,024 
(52%) were not bacteriologically confirmed (indeterminate) and 167 (9%) were not 
tuberculosis cases (in whom non-tuberculosis mycobacteria [NTM] were isolated). Of 
the 1,973 cases, 1,716 (87%) had been treated with anti-tuberculosis drugs, while 
257 (13%) had not been treated. Of the 782 bacteriologically confirmed cases, 68 
(8.7%) were misclassified as non-notifiable (32 [4.1%] had their diagnosis changed by 
a clinician and 36 [4.6%] by administrative coding). Of the 167 cases in whom NTM 
were isolated, 72 (43.1%) were misclassified as tuberculosis cases. Of the 257 
untreated individuals with suspected tuberculosis, 31 (12.1%) did not have any 
evidence of tuberculosis (20 indeterminate and 11 NTM cases) and were 
questionably classified as newly diagnosed cases. Thus, at least 140 (14.8%) were 
‘misclassified’ based on logical in-consistency and only 809 (85.2%, 95%CI 82.8–87.4) 
were correctly classified. The null hypothesis was rejected and we concluded that 
there was substantial misclassification of notified tuberculosis cases in Taipei in 2003.
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5. Discussion 
 
To systematically address findings and implication of these studies, overall discussion 
of each paper addresses general perspectives, strengths, weaknesses, and impact of 
the study, as well as further actions required.  There were common strengths of 
these papers. First, these studies were done independently without any interference 
of health authorities. Taiwan CDC as the funding agency played no role in data 
analysis and publication. Second, quality of data collection and management were 
assured through training and double data entry. Third, a very high proportion of the 
eligible population was included to avoid selection bias. Fourth, clear definitions 
were applied in outcome assessment to avoid information bias. Fifth, potential 
determinants were analyzed to address confounders. Finally, findings of these 
studies have contributed to policy change. An over-riding weakness of these studies 
was that the study population was restricted to 4 laboratories (paper 1) and Taipei 
(papers 2-6) and findings may not be generalized to the whole Taiwan.  
 
5.1 External Quality Assessment of smear microscopy 
 
External Quality Assessment (EQA) is a process to assess laboratory performance, 
which includes panel testing (evaluating performance by slides from the central 
laboratory to peripheral centers), blinded rechecking (monitor performance by a 
sample of slides from the peripheral laboratories to a higher-level laboratory for 
rereading) and on-site evaluation.96 The objective of EQA is the identification of 
laboratories with serious problems resulting in poor performance, not the 
identification of individual slide errors or the validation of individual patient 
diagnoses.  
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This was the first study ever carried out on the quality of smear microscopy in Taiwan. 
Four mycobacteriology laboratories collected slides from their routine work for the 
training course. These slides likely were representative of the actual performance of 
smear microscopy of these laboratories. Course participants followed advice of 
international laboratory experts in using internationally recommended methodology 
to evaluate these slides. Findings were confirmed by instructors of the training 
course and likely represent an un-biased assessment of these slides.  
 
There were some limitations of this study. It did not include all mycobacteriology 
laboratories in northern Taiwan. The four laboratories enrolled were not a random 
sample of all laboratories. It was an opportunistic study taking advantage of a 
training course. Therefore, findings of this study may not be generalizable to other 
laboratories in Taiwan. However, the finding of the exercise in the training course was 
alarming. A high proportion of smears was judged to be of poor quality. Two (50%) of 
the 4 laboratories had at least one high false negative and 3 (75%) laboratories had at 
least one low false negative result. Given that these 4 mycobacteriology laboratories 
were considered to be the most experienced mycobacteriology laboratories in 
northern Taiwan, these negative findings call for corrective action.  
 
These findings obtained immediate attention of Taiwan CDC who subsequently 
conducted 3 workshops on EQA of sputum smear microscopy in each of the northern, 
central and southern regions of Taiwan in 2005. A pilot smear EQA program that 
involved Taiwan CDC-contracted mycobacteriology laboratories was also launched in 
2005. Of the 1,017 slides sampled in 2005, 637 (63%) had proper smear size, 492 
(48%) proper thickness and 884 (87%) proper staining. Rechecking of 981 readable 
slides in 2005 identified 3 (0.3%) high false-negatives, 3 (16.7%) low false-positives 
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and 26 (2.8%) low false-negatives. Of the eight laboratories, only two (25%) reached 
80% sensitivity in 2005; 2 (25%) had at least one major error and 7 (78%) had at least 
one minor error.97These findings were similar to our findings.  
 
After conducting the rechecking program in 2005, an extensive technical training 
course was offered at the national reference laboratory. One medical technologist 
from each contracted laboratory attended the course. The content of the course 
included slide preparation and reading, internal quality control and assessment. A 
certificate was given to participants who passed the technical evaluation. During an 
on-site evaluation, discordant slides were returned to each laboratory, and one of the 
laboratory technologists analyzed these discordant slides in the presence of the 
laboratory technologists during on-site evaluations. Laboratory facilities and 
procedures for slide preparation were also evaluated. These efforts resulted in 
improvement in the rechecking program in 2006. For the 972 slides rechecked in 
2006, 972 (100%), had proper smear size, 748 (77%) proper thickness and 809 
(99.6%) proper staining. Of the 9 laboratories that participated, 2 laboratories 
reached 80% sensitivity in 2005, which increased to 4 in 2006. However, 3 (0.3%) 
high false-negatives, 8 (28.6%) low false-positives and 12 (1.3%) low false-negatives 
were still identified. Of the 9 laboratories, 2 (25%) had at least one major error and 8 
(89%) had at least one minor error.97 The average number of slides examined in 
laboratories using the Kinyoun staining method was approximately 40 (range 25–50) 
per technologist per day, whereas the average number in laboratories using a 
fluorescence staining method was 59 (range 35–100). In 3 laboratories, technologists 
were also responsible for performing culture and drug susceptibility testing. Heavy 
workload remained a major concern for those laboratories with false-negatives. 
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Clearly, results of the rechecking program in 2006 deserved attention. Smear 
microscopy remains the cornerstone for the diagnosis of pulmonary tuberculosis in 
adults because it identifies the most powerful sources of transmission of 
tuberculosis. The main problem is that it is tedious, requiring motivated staff, with 
increasing risk of false-negative error when large numbers of specimens are 
examined. 98 Therefore, an effective EQA system is essential. Performance evaluation 
of Taiwan CDC contracted laboratories revealed a relatively low sensitivity in 
detecting smears positive for acid-fast bacilli, which was detrimental to the diagnosis 
of pulmonary tuberculosis. False negatives were mainly due to high workload of 
laboratory technologists. Increased payment of smear microscopy by national health 
insurance, reducing workload of laboratory technologists who are responsible for 
smear microscopy, on-the-job training to ensure capacity in reading slides, and 
means to increase motivation of laboratory technical personnel may be elaborated 
to help improve the quality of smear microscopy. To date the EQA program is limited 
to only 9-10 laboratories contracted by Taiwan CDC. There are plenty of laboratories 
in general hospitals performing smear microscopy whose quality has never been 
externally assessed. It is essential to establish a quality assured microscopy network 
in Taiwan; strategy to ensure the quality of smear microscopy at general health care 
facilities must be developed.  
 
5.2 Tuberculosis-related death without treatment 
 
Failure of diagnosis as a factor in tuberculosis mortality has been reported previously. 
Among patients who died from tuberculosis, the proportion who died without 
treatment was 47.4% in Canada99 and 53.1% in Norway100. Death before notification 
was noted in the 1990s in Taiwan, and was mainly due to delays in notification; it was 
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not specified whether patients had received anti-tuberculosis treatment before 
death.91A study in the United States reported that 5.1%101 of TB cases were 
diagnosed after death; another study in San Francisco reported that 3.9%102 of 
tuberculosis cases were diagnosed after death. 
 
The problem of tuberculosis-related death without treatment has not been 
addressed previously in Taiwan. We observed that some notified culture-positive 
tuberculosis patients had not been treated with anti-tuberculosis drugs in a timely 
manner, and some of them died without anti-tuberculosis treatment. Therefore, we 
kept track of a cohort of notified culture-positive tuberculosis patients in Taipei City 
to investigate tuberculosis-related death without treatment. Overall, of the 536 TB 
patients who were culture-positive for M. tuberculosis, 97 (18.1%) died, of whom 26 
(26.8%) died without anti-tuberculosis treatment. As reporting of tuberculosis is 
mandatory by law and all culture positive tuberculosis patients in Taipei in 2003 were 
included, the study population likely was representative of Taipei. We found that the 
majority (88.5%) of the tuberculosis patients who died without treatment were aged 
65 years or more, and 76.9% of these died before the results of sputum culture were 
available. Clearly, clinicians need to maintain a high level of awareness of 
tuberculosis and initiate anti-tuberculosis treatment as early as possible, especially 
among the elderly who are very ill or with co-morbidity, if the probability of 
tuberculosis is high. New diagnostics with a higher sensitivity in detecting smear 
negative tuberculosis103, 104 might be helpful and their utility in reducing 
tuberculosis-related death without treatment needs to be evaluated.  
 
This study likely underestimated the frequency of tuberculosis-related death without 
treatment, as autopsies were rarely performed in Taiwan and those who did not 
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undergo sputum examination would not be included. Further, we did not consult 
laboratory registers to evaluate completeness of reporting of bacteriological 
confirmed cases. Laboratory registers provide information on cases with acid fast 
bacilli and/or M. tuberculosis, allowing investigation of initial defaulters as well as 
tuberculosis-related death without treatment. Rates of initial defaulters, defined as 
patients who were smear-positive on the laboratory register but who were not 
registered for anti-tuberculosis treatment, have been reported to be 17% in Cape 
Town, South Africa,105 and 4.5% in Andhra Pradesh, India.106  
 
Rates of initial loss-to-follow-up and the interval from a positive sputum result (either 
smear or culture) to initiation of treatment are issues to be further investigated in 
Taiwan. For surveillance of tuberculosis, cross-checking laboratory registers and 
national tuberculosis registry should be done to assess completeness of reporting of 
bacteriologically positive patients. Further, tuberculosis-related deaths without 
treatment should be highlighted in the annual reports and a strategy to prevent this 
from happening need to be developed.    
 
5.3 Factors associated with a clinician's decision to stop anti-tuberculosis treatment 
before completion 
 
The International Standards for Tuberculosis Care has advised that all patients 
suspected of having pulmonary tuberculosis should have at least two sputum 
specimens submitted for microscopic examination in a quality-assured laboratory 
and that all persons with chest radiographic findings suggestive of tuberculosis 
should have sputum specimens submitted for microbiological examination.107 A 
survey of TB services in hospitals in seven large cities in Asia and North Africa 
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demonstrated that a high proportion of hospitals did not always perform sputum 
smear examinations for individuals with suspected tuberculosis.108 In Korea in the 
1990s, more than 50% of general practitioners did not consider sputum examination 
essential in the diagnosis of tuberculosis.109 In a study in South Africa, chest 
radiography alone was used to diagnose pulmonary tuberculosis in 45% of the 
records reviewed.110 Our study showed that clinicians’ practices in diagnosing 
pulmonary tuberculosis in health care facilities in Taipei City were not standardized. A 
high proportion of individuals were put on anti-tuberculosis treatment based on CXR 
findings before sputum examination. This practice should be discouraged; it may lead 
to delays in the diagnosis of lung cancer and other diseases and result in 
over-diagnosis of smear- and culture-negative tuberculosis, exposing the patients to 
unnecessary or wrong treatment. Sputum culture contributed positively to the 
diagnosis of tuberculosis in this series of patients. However, positive sputum culture 
also resulted in anti-tuberculosis treatment being started for a considerable number 
of patients in whom non-tuberculosis mycobacteria were isolated. This highlighted 
the importance of rapid species identification so that adequate treatment tailored to 
the species of mycobacterium can be initiated in a timely manner, if indicated.  
 
Change of diagnosis and de-notification of tuberculosis have rarely been previously 
investigated. There have been studies on adequacy of presumptive diagnosis of 
smear negative pulmonary tuberculosis based on radiographic findings. Gordin and 
colleagues analyzed 139 smear negative patients who were treated for a 
presumptive diagnosis of pulmonary tuberculosis and reported that 66 (48%) were 
determined to have current tuberculosis (16 had a positive culture, 43 had 
radiographic improvement, and 7 clinical improvement)111. Lee and colleagues 
investigated 101 smear negative presumptive pulmonary tuberculosis cases and 
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found that 61 (62.4%) had radiographic improvement (32 culture positive).112 Our 
study did not specifically address adequacy of presumptive diagnosis of pulmonary 
tuberculosis but rather changed diagnosis and de-notification of tuberculosis at 
program level. Of the 1,126 pulmonary tuberculosis patients, 156 (13.9%) had their 
diagnosis of tuberculosis changed by a clinician and were de-notified. Patients whose 
treatment was started based on CXR alone were significantly more likely to have their 
treatment stopped by a clinician. This demonstrates why radiographic findings should 
not be used alone to diagnose tuberculosis. Among the various categories of patients, 
indeterminate cases were most likely to have their diagnosis changed (24.4%). 
Indeterminate patients who visited other health facilities were more likely to be 
advised to stop anti-tuberculosis treatment than those who continued treatment at 
the diagnosing facilities. This probably reflected inter-personal disagreement in the 
diagnosis of smear- and culture-negative tuberculosis, highlighting the importance of 
standardizing the diagnosis of non-bacteriologically confirmed tuberculosis. Several 
definite tuberculosis cases were advised to stop treatment, particularly those who 
continued treatment at other health facilities, and subsequently required 
retreatment of tuberculosis. This highlighted poor communication and inadequate 
coordination between health facilities. Health services need to strengthen the 
coordination of case management of tuberculosis patients who visit other health 
facilities during treatment. Among those whose treatment was stopped, several 
patients had in fact interrupted treatment for at least 2 consecutive months. 
Classifying treatment interruption as having a change in diagnosis obscured the 
problem of treatment interruption and lost the opportunity to address this important 
issue. This was unintended misclassification at central level of the surveillance system 
but a consequence of systematic under-detection of treatment interruption.     
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This likely is the first study that comprehensively investigated clinical practice in the 
diagnosis of tuberculosis and subsequent change of diagnosis of tuberculosis by 
clinicians. The limitation of this study was that we did not comprehensively follow up 
patients who were advised to stop anti-tuberculosis treatment to determine what 
happened at a later point in time.  
 
Findings of this study contributed to the development of a policy of Taiwan CDC that 
bacteriologically-negative cases whose diagnosis of tuberculosis cases was judged to 
be questionable, cases whose diagnosis of tuberculosis was changed after initiation 
of anti-tuberculosis treatment and retreatment cases without bacteriological 
evidence should be reviewed by an expert committee at regional branches of Taiwan 
CDC. The expert committee consisted of several senior clinicians with substantial 
experience of tuberculosis. Review of questionable cases by the expert committee 
may contribute to improvement of diagnosis and surveillance of tuberculosis and 
reducing inappropriate discontinuation of treatment of definite cases. However, as 
the expert committee did not review all bacteriologically-negative cases at the outset 
of treatment, the impact of this mechanism remains to be evaluated.  
 
5.4 Prescribing practices for anti-tuberculosis drugs in the treatment of tuberculosis 
 
An evaluation of the routine prescribing practices and dosages for anti-tuberculosis 
medications was done in Kenya, Malawi, Nepal and Senegal, which reported that the 
proportion of patients treated with adequate dosages of anti-tuberculosis drugs 
varied.113, 114  
 
Our study revealed that prescribing practices for anti-tuberculosis drugs in Taipei City 
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were unsatisfactory. Almost 40% of tuberculosis patients did not have their 
pretreatment body weight recorded. Among those with pretreatment body weight 
recorded, the dosages of anti-tuberculosis drugs prescribed were often too low or 
too high, a finding of serious concern. This finding challenged the naïve assumption 
that after integration of tuberculosis services into general health care system 
supervision and monitoring was not required.  
 
Inappropriate prescribing of the 3-drug FDC may be due to the strength of the 
preparation available in Taiwan (isoniazid, H 80 mg + rifampicin, R 120 mg + 
pyrazinamide, Z 250 mg). The ratios of H, R and Z in the 3-drug FDC was 1:1.5:3.1 
which deviated from the ratios (1:2:5) of recommended dosage in milligrams (mg) 
per kilogram (kg) body weight of H (5 mg/kg), R (10 Mg/kg), and Z (25 mg/kg).115 The 
amount of H per tablet is relatively high and that of Z relatively low. The equivalent 
strength of the 3-drug FDC recommended by the WHO is H 75 mg, R 150 mg and Z 
400 mg per tablet and the ratios of H, R, and Z are 1:2:5.3, which were more 
consistent with the ratios of recommended dosage of H, R, and Z. The issue of 
imbalanced strength also applied to one formulation of 2-drug FDC (H 100+ R 150, 
HR ratio 1:1.5) but not another (H 150 + R 300, HR ratio 1:2) 
 
This is the first study on dosing of anti-tuberculosis drugs in Taiwan. As it included 
almost all cases in Taipei in 2003, findings of this study might be generalizable to 
other parts of Taiwan where monitoring and supervision were also not done. This 
study has several limitations: first, we did not keep track of modifications of regimens 
during anti-tuberculosis treatment, and clinicians may have changed the dosages 
prescribed. Second, we did not assess the frequency of adverse reactions among 
patients who received higher-than-recommended dosages. Third, we did not 
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evaluate the association between dosages and either treatment outcome (failure and 
relapse) or the development of drug resistance.  
 
The findings of this study were reported to Taiwan CDC in December 2005. 
Subsequently, Taiwan CDC has taken action to address the issue of substandard 
regimens and inadequate dosing. Several training courses on the diagnosis and 
treatment of tuberculosis were held. In 2006, the information system has been 
revised to routinely capture body weight of notified tuberculosis cases. In 2007, 
public health nurses have been trained to cross-check clinicians’ prescription of 
anti-tuberculosis drugs according to guidelines for anti-tuberculosis treatment and to 
communicate with clinicians in case of inconsistency. If dosing remained inconsistent 
after communicating with clinicians, public health nurses should report these cases in 
meetings of tuberculosis expert committees. The expert committee would review 
clinical information of these cases and made recommendations, which would be 
provided to clinicians. In 2007, Taiwan CDC evaluated a random sample of 108 
tuberculosis patients and found that 28.7% received inadequate dosage of drugs and 
14.8% received lower-than-recommended dosage of rifampicin.116 Subsequently, 
Taiwan CDC collaborated with the NHI program to promote standardized regimens 
and reduce reimbursement for inadequate tuberculosis regimen.117 Preliminary data 
show that non-standardized regimen and inadequate dosing have been reduced 
substantially.118 A study assessing prescribing practices in the treatment of 
tuberculosis in Taipei conducted in 2011 revealed that the proportion of culture 
positive tuberculosis patients without recorded pre-treatment body weight was 
12.6% in 2007, which decreased to 0.5% in 2008 and none in 2010. (Chiang C-Y, 
manuscript submitted). Among those who were prescribed with 3-drug FDC, the 
proportion with dosage consistent with Taiwan CDC guidelines was 83.7% in 2007, 
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which increased to 91.4% in 2010, and the proportion with lower-than- 
recommended-dosage was 7.4% in 2007, which decreased to 1.9% in 2010. (Chiang 
C-Y, manuscript submitted) 
 
5.5 Outcome of Tuberculosis: factors associated with treatment interruption for 2 
months and death (Paper 5) 
 
Traditionally, outcomes of anti-tuberculosis treatment in Taiwan were determined 18 
months after the close of the year in which these cases were registered. This 
approach was insensitive to events that have important repercussions for National 
Tuberculosis Programs, such as treatment interruption for 2 months and remaining 
sputum-positive after 5 months of treatment. The proportion of TB patients lost to 
follow-up was 8.9% in the cohort of patients registered in 1997. To improve TB 
treatment outcome, Taiwan CDC has strengthened case holding in recent years. The 
proportion of patients who were lost to follow-up before completing a full course of 
treatment decreased substantially as a result. While this is remarkable progress in 
streamlining the national tuberculosis program, the next step should be to identify 
patients who interrupted treatment for at least 2 months and to address these 
events efficiently. Our study revealed that among 1,016 tuberculosis patients in the 
2003 Taipei cohort who were classified as treatment success by Taiwan CDC, 63 (6.2%) 
had interrupted treatment for 2 months (treatment interruption) and 29 (2.9%) 
remained sputum positive at 5 months (failed); of the 171 patients who were 
classified as dead, 10 (5.8%) had interrupted treatment for 2 months (treatment 
interruption) and 7 (4.1%) remained sputum positive at 5 months (failed). Clearly, the 
surveillance system overestimated the proportion successfully treated and died, but 
under-estimated the proportion lost to follow-up and failed.  
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A limitation of this study was that it included only tuberculosis cases registered in 
Taipei but not other parts of Taiwan. However, it clearly pointed out constraints of 
the surveillance system and contributed to a change of policy of Taiwan CDC in 
strengthening identification of patients who interrupted treatment for 2 months and 
patients who remained sputum positive at 5 months of treatment or later. According 
to official reports of Taiwan CDC, the proportion of tuberculosis patients who 
interrupted treatment for 2 or more months was 0.6% for patients notified in 2004, 
2.3% in 2005, 3.6% in 2006, and 2.8% in 2007; the proportion of patients who were 
sputum positive at 5 months or later was 0.6% in 2004, 1.7% in 2005, 1.6% in 2006 
and 2.9% in 2007. These did not indicate an actual increased proportion of treatment 
interruption or failed from 2004 to 2007; it reflected the results of strengthening 
identification of treatment interruption and failed.   
 
A comparison with national mortality rates shows that all-cause mortality among TB 
patients on treatment was 8.7 times higher than that of the general population. In 
England and Wales, all-cause mortality among patients with pulmonary tuberculosis 
was 10 times greater than that of the age- and sex-matched general population.119 
The excess mortality in this cohort is particularly high among younger members of 
the population, as was reported in the Netherlands.120 Our study revealed that the 
proportion of tuberculosis patients on treatment who died was relatively high 
(16.8%). The majority (75%) died within 3 months of treatment. The proportion who 
died was higher among the elderly and those with concomitant diseases. Late 
presentation, health system delay in the diagnosis and initiation of treatment, or 
rapid disease progression in the presence of co-morbidities were possible factors 
related to death. A strategy to reduce tuberculosis case fatality needs to be 
developed.  
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5.6 Tuberculosis surveillance system (Paper 6)  
 
Since 1997 when CDCB published the first annual tuberculosis control report, all 
notified tuberculosis cases were classified into one of the following categories: 1) 
foreigner: those who were not citizens of Taiwan; 2) died before registration; 3) 
treatment completed before registration; 4) diagnosis changed: those who were 
initially notified but who subsequently had their diagnosis changed to non-notifiable; 
and 5) newly diagnosed tuberculosis cases: those who did not fit into any of the 
above categories. Until 2002, the records of all reported tuberculosis cases were 
reviewed by a medical officer assigned to each city/county to verify whether or not 
they fitted the definition for tuberculosis. Anti-tuberculosis treatment was initiated if 
a medical officer confirmed the diagnosis of tuberculosis. As such, all notified cases 
classified as a tuberculosis case were put on anti-tuberculosis treatment.   
 
This practice was discontinued after the responsibility of tuberculosis program was 
transferred from the former CDCB to Taiwan CDC. No medical officers were tasked 
with the duty to verify the accuracy of case notifications and the classification did not 
take into account whether or not a patient was under anti-tuberculosis treatment. To 
calculate the notification rate of tuberculosis among citizens, a non-physician public 
health specialist within the Taiwan CDC downloads individual information on all cases 
notified in the previous year from the internet-based reporting system on 30 
September each year (this was changed to April 30 since 2006, Yang S-L, personal 
communication), and subtracts those who are foreign citizens, those who died before 
registration, those whose treatment was completed before registration, and those 
whose diagnosis was changed by a clinician. The specialist then identifies those cases 
without bacteriological confirmation in whom no improvement was reported 
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following anti-tuberculosis treatment and those who have died but in whom 
tuberculosis was not recorded on the death certificate, includes these cases in the 
‘diagnosis changed’ category (in this case by ‘administrative coding’), and then finally 
subtracts these cases to obtain the annual notification of tuberculosis cases among 
Taiwanese citizens. In this practice, accuracy in the classification of notified 
tuberculosis cases heavily depends on the completeness and timeliness in obtaining 
accurate bacteriology results and clinical response to anti-tuberculosis treatment 
from general health care facilities.    
 
Our study identified substantial errors in the classification of reported tuberculosis 
cases in Taipei. One limitation of this study was that we did not follow up those cases 
who were classified as non-notifiable by administrative coding to see what happened 
to them. However, findings of this study were likely generalizable and reflected the 
practice for the whole of Taiwan. Classifying cases determined as non-notifiable by 
administrative coding in the category ‘diagnosis changed’ is a questionable practice 
and is misleading, resulting in a substantial increase in the number of cases with 
‘diagnosis changed’. One of the major causes of misclassification was correct 
determination of whether anti-tuberculosis treatment was initiated and that clinical 
information has not been completely updated in a timely manner to local health 
authorities and Taiwan CDC.94, 121 Consequently, bacteriologically-confirmed cases 
were classified as non-notifiable because positive bacteriological results, especially 
culture, were not reported to local health authorities and Taiwan CDC. Likewise, 
patients from whom NTM were isolated were not de-notified and were classified as 
tuberculosis cases because results of species identification were not updated. To 
improve accuracy of the surveillance system, the communication of information 
between general health care facilities and the health authority should be complete, 
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timely and accurate.  
 
Since the study on misclassification of reported tuberculosis cases, Taiwan CDC has 
strengthened surveillance data by systemically and periodically sending reminders 
for updating clinical information. Further, non-notifiable cases were classified into a) 
diagnosis changed by clinician, b) NTM, and c) does not fit with criteria of a 
tuberculosis case. The number of patients in the last category has decreased 
substantially from 1350 (5.6%) in 2004 to 34 (0.2%) in 2009 (personal 
communication, Yang S-L, Taiwan CDC). It is likely that misclassification of notified 
cases has decreased considerably. However, Taiwan CDC should regularly carry out 
supervision and monitoring to ensure the quality of reporting and communication. 
 
Apart from Taiwan, reporting individuals who have no bacteriological evidence of 
tuberculosis and are not treated with anti-tuberculosis drugs is rare. To strengthen 
tuberculosis surveillance in Taiwan, it is essential to find out whether reporting 
bacteriologically negative individuals who are not treated with anti-tuberculosis 
drugs contribute to surveillance of tuberculosis in a positive manner. Reporting of 
individuals with suspected communicable diseases is mandatory by the article 39 of 
the communicable disease control act, stating that: “when physicians or forensic 
physicians detect communicable diseases or suspected communicable diseases in 
patients or corpses during the process of diagnosis and treatment or during the 
examination of the corpses, they shall immediately take the necessary infection 
control measures and report such cases to the competent authorities in the locality”. 
Accordingly, Taiwan CDC indicate criteria of tuberculosis reporting122 as the 
following : a) persons with signs and symptoms of tuberculosis, such as chronic 
cough, weight loss, fever or radiographic findings suspected with tuberculosis, b) 
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clinical specimens culture positive for M. tuberculosis, c) clinical specimen smear 
positive for acid-fast bacilli, d) pathological findings consistent with tuberculosis. 
Criteria a) was not precise and allows different reading. Monitoring and evaluation 
on reporting individuals who fit criteria a) is extremely difficult, if not impossible. 
However, a substantial number of cases who did not fulfill criteria b), c) and d) 
(bacteriologically / pathologically negative) and were not judged to require a course 
of anti-tuberculosis treatment were being notified. The majority of these cases were 
classified as non-notifiable and a minority might be questionably classified as 
tuberculosis cases, as demonstrated by our study. Public health action without clear 
guidance or definition is potentially confusing and misleading, and runs the risk of 
losing focus. It is essential to evaluate critically whether reporting of individuals who 
have no bacteriologically / pathologically evidence of tuberculosis and are not 
judged to require a course of anti-tuberculosis treatment provides any public health 
benefit, and whether this practice imposes confusion and unnecessary burden on 
public health system. To be in line with the communicable disease control act on 
reporting individuals with suspected communicable diseases, Taiwan CDC may seek 
consultation on the feasibility of defining “suspected tuberculosis that required 
reporting” as individuals with suspected tuberculosis who require a course of 
anti-tuberculosis treatment judged by a qualified clinician.   
 
A recently published study on completeness and timeliness of tuberculosis 
notification in Taiwan reported that there were 209,095 patients who had 
tuberculosis-related ICD-9 codes in the year 2005–2007 in the NHI reimbursement 
database, in whom 144,718 (69.2%) were newly assigned with tuberculosis-related 
ICD-9 codes in the year 2005–2007. Of these 144,718 patients, 84,361 (58.3%) were 
not prescribed any anti-TB drugs within 6 months after being assigned 
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tuberculosis-related ICD-9 codes, 57,405 (39.7%) were prescribed 2 or more types of 
anti-tuberculosis drugs. Of these 57,405 patients, 52,763 (91.9%) were new 
tuberculosis cases and 4,642 (8.1%) were retreatment cases who had been notified 
previously. Of the 52,763 new tuberculosis cases, 1,270 (2.4%) were not notified, and 
of the 4,642 retreatment cases, 844 (18.2%) were not notified.123 Taiwan CDC should 
elaborate whether it would be more practical and effective to ensure complete and 
timely reporting of: 1) all cases who are treated with 2 or more anti-tuberculosis 
drugs, no matter whether they are bacteriologically / pathologically positive; and 2) 
all cases with positive bacteriologically / pathologically finding (smear positive for 
acid-fast bacilli, culture positive for M. tuberculosis, line probe assays or Xpert® 
MTB/RIF positive, or pathological findings consistent with tuberculosis), no matter 
whether they have been treated with anti-tuberculosis drugs.  
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6. Conclusions and Recommendations 
 
6.1 Conclusions  
 
The general objective of this study was to assess tuberculosis services and 
surveillance after the integration of the vertical tuberculosis program into the 
general health care system in 2001. Several constraints of tuberculosis services were 
identified.  
1. The quality of smear microscopy of 4 mycobacteriology laboratories who 
provided slides for a training course in 2004 was not satisfactory.  
2. The number of tuberculosis-related deaths without treatment in Taipei in 
2003 was substantial.  
3. A high proportion of tuberculosis patients in Taipei in 2003 were treated with 
anti-tuberculosis drugs on the basis of radiographic findings and 
subsequently were advised to stop anti-tuberculosis treatment before 
completion.  
4. Prescribing practices for anti-tuberculosis drugs in the treatment of 
tuberculosis in Taipei in 2003 was substandard.   
5. Treatment interruption for 2 consecutive months and sputum positive at 5 
months or later among tuberculosis patients in Taipei in 2003 was largely 
under-detected. A relatively high tuberculosis case fatality ratio was related to 
old age and co-morbidity.  
6. There were substantial mis-classification of notified tuberculosis cases in 
Taipei in 2003, largely due to failure to take into account whether 
anti-tuberculosis treatment is initiated and due to incomplete update of 
bacteriological results and clinical response.    
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6.2 Recommendations 
 
It is recommended that health authorities and Taiwan CDC: 
1. Extend EQA of smear microscopy to all mycobacteriology laboratories of general 
health care facilities in Taiwan. 
2. Address initial loss-to-follow-up and tuberculosis-related death without 
anti-tuberculosis treatment.  
3. Assess clinicians’ practice in the diagnosis and treatment of tuberculosis as well 
as stopping anti-tuberculosis treatment before completing a full course.  
4. Conduct regular clinical audit on prescription practices of anti-tuberculosis drugs. 
5. Closely monitor loss-to-follow-up and failure in the treatment of tuberculosis as 
well as develop a strategy to reduce case fatality of tuberculosis. 
6. Critically review the policy of tuberculosis notification and evaluate the quality of 
surveillance of tuberculosis. 
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7 Epilogue: from a vertical program to an integrated approach 
 
After taking over the responsibility of the tuberculosis program, Taiwan CDC has 
implemented several important activities: 
1. Established a national reference laboratory (NRL) in 2004: the NRL has 
established the capacity in performing RFLP, spoligotyping, and MIRU-VNTR 
for molecular epidemiological studies of tuberculosis,124, 125 has conducted 
EQA of smear microscopy in CDC contracted laboratories,97 has carried out 
proficiency testing of drug susceptibility test in almost all laboratories that 
performed anti-tuberculosis drug susceptibility testing,126 and has pilot tested 
rapid diagnosis of drug resistant tuberculosis,127 and other laboratory-related 
activities.   
2. Collaborated with professionals and specialists to publish guidelines for the 
diagnosis and treatment of tuberculosis in 2004 (2nd edition in 2006, 3rd 
edition in 2008, 4th edition in 2011). 
3. Established an “expert committee” at each regional branch” to provide 
guidance in the diagnosis and treatment of tuberculosis in 2004   
4. Involved the private sector by an incentive mechanism through the national 
health insurance program in 2004. 
5. Reinforced the examination of 3 sputum specimens among all notified 
pulmonary tuberculosis cases in 2005. 
6. Strengthened infection control for tuberculosis in 2005. 
7. Strengthened tuberculosis services in aboriginal areas in 2005.   
8. Monitored tuberculosis outbreaks in long-term care facilities and congregate 
settings in 2006.128 
9. Launched an ambitious plan entitled “mobilization of all citizens to reduce 
 76
incidence of tuberculosis by half in 10 years” in 2006, aiming to reduce 
incidence of tuberculosis to 34 per 100 000 by 2015, in which 15 plans of 
“Find tuberculosis and Cure tuberculosis” were listed. The budget for this 
program (NT$ 8.4 billion for 5 years) was estimated to be 40 times more than 
that of CDCB before re-structuring (NT$ 40 million per year, Lin T-P, former 
director of CDCB, personal communication).  
10. Implemented a directly-observed therapy (DOT) program in 2006. To date, 
more than 680 outreach workers have been hired to carry out DOT. The 
proportion of bacteriologically confirmed tuberculosis cases treated under 
DOT was 50% in 2006, which increased to 92% in 2010.129 
11. Promoted standardization of tuberculosis regimens through national health 
insurance program in 2008. 
12. Implemented a program for management of drug-resistant tuberculosis in 
2007, which has effectively reduced treatment interruption of MDR-TB 
patients to a very low level.  
13. Strengthened contact management in 2007.130 
14. Initiated treatment of latent infection with M. tuberculosis by 
directly-observed preventive therapy in 2008. 
15. Implemented accreditation of mycobacteriology laboratories in 2008. 
16. Strengthened bio-safety of mycobacteriology laboratories in 2009.  
17. Strengthened tuberculosis services among the poor in 2010. 
18. Pilot tested a new mechanism of external ‘tuberculosis adviser’ at hospitals 
with a high number of notified tuberculosis cases in 2011 
 
Correction of the constraints on tuberculosis services in the transition from a vertical 
system to a fully integrated approach identified by our studies would have had no 
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impact at all if Taiwan CDC neglected these findings. Fortunately, Taiwan CDC acted 
positively rather than defensively to the findings described in this thesis and has 
taken actions to meet the challenges.131 Taiwan tuberculosis control reports were 
published annually from 1997-2001. After interruption of a few years, Taiwan CDC 
has begun to publish an annual tuberculosis control report.132 In 2009, a total of 
13,336 new tuberculosis cases were notified; 79% of pulmonary tuberculosis cases 
were either smear positive and/or culture positive.133 Tuberculosis notification rate 
was 57.8 per 100,000 population, representing a 20.3% reduction since 2005. 
Tuberculosis notification rate was highest in Eastern Taiwan (110.7 per 100,000), by 
region. Males had higher rates than females (79.6 vs 35.6 per 100 000 population). 
Those aged 65 years or more accounted for 53.1% of total new tuberculosis cases, 
and those aged 45-64 years accounted for another 26.2%, reflecting age transition of 
tuberculosis patients from the younger age group (25-44 year-old accounts for 50.9% 
of tuberculosis cases registered in 1957-1961)134 to the elderly in past five decades in 
Taiwan.  
 
The proportion of new tuberculosis cases who were HIV positive was 0.7%. 
Treatment outcome at 12 months among those registered in 2007 was as follows: 
71.1% treatment success, 18.4% died, 2.9% failed, 2.8% interrupted treatment for 2 
or more months, 0.1% transferred, and 4.8% still on treatment or not evaluated. The 
proportion of tuberculosis patients who died was relatively high among those aged 
50 years or more (figure 11).  
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Figure 11. Outcome of smear-positive tuberculosis, 2008, Taiwan, by age group 
 
One of the most important challenges after re-structuring the tuberculosis service 
system from a vertical program to a fully integrated approach was that there was no 
health care facility under the direct command of Taiwan CDC; tuberculosis services 
were provided at general health care facilities through NHI program. There was one 
hospital specialized in tuberculosis and lung disease (Chest Hospital in Tainan, which 
was one of the regional Branches of former CDCB), which was operated in a manner 
similar to general hospitals through the NHI program. No hospital is currently 
designated as a tuberculosis hospital taking tuberculosis control as primary 
responsibility. While reporting of tuberculosis has been mandatory, Taiwan CDC 
operating in parallel with the health care system has limited capacity in strengthening 
case finding and the diagnosis of tuberculosis within general health care system. 
While Taiwan CDC can strengthen health education on tuberculosis and encourage 
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symptomatic inhabitants to seek health care (to shorten patient delay), health care 
facilities are not equally competent in efficient identification of individuals with 
suspected tuberculosis for further examinations. A study conducted in Southern 
Taiwan reported that health system delay was much longer than patient delay.135 
Tuberculosis patients who visit health care facilities may not be identified; if 
identified, sputum examination may not be done; if it is done, the quality of sputum 
examination may be inadequate; if they are positive on sputum examination, they 
may not be put on anti-tuberculosis treatment; on the other hand, patients who have 
no tuberculosis may be unnecessarily treated with anti-tuberculosis drugs at the 
hands of inexperienced clinicians. Consequently, health system delay in the diagnosis 
and treatment of tuberculosis could be particularly long in some facilities; 
overdiagnosis of tuberculosis by inexperienced clinicians impose an unnecessary 
burden of registration, case management and contact tracing of public health system. 
 
As timely diagnosis and effective treatment of tuberculosis is the cornerstone of 
tuberculosis service, no tuberculosis program can avoid the challenge of clinical 
management of tuberculosis, especially in the private sector. As tuberculosis has 
become a relatively uncommon disease in Taiwan, most clinicians are not efficient in 
timely diagnosis and proper treatment of tuberculosis. Engagement, training, 
monitoring and supervision of the private sector are essential. Public-public and 
public-private mix approaches and International Standards for Tuberculosis Care 
(ISTC) have been listed within the component “engage all care providers” of the Stop 
Tuberculosis Strategy. However, ISTC presents what should be done but does not 
address how the action is to be accomplished.107 Tuberculosis programs need to 
develop local policies and procedures to ensure the quality of tuberculosis services. 
Program-relevant operational research can identify constraints with implications for 
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policy change, as demonstrated by our studies in relation to tuberculosis services in 
Taiwan. To strengthen tuberculosis services in Taiwan, an in-built budget for 
operational research must be protected.  
 
There are several elements of the health care system that help address constraints of 
tuberculosis services in Taiwan. The communicable disease control act has been in 
place to ensure tuberculosis reporting. The national health insurance program not 
only facilitates access to care, but also provides a basis for monitoring and regulation 
of diagnosis, treatment and reporting of tuberculosis. Through various mechanisms 
of national health insurance, health authorities and Taiwan CDC have access to 
clinical information of tuberculosis patients (including detail bacteriological 
examinations, drugs prescribed and dosages administered) at almost all health care 
facilities. Further, tuberculosis case managers are in place in most hospitals to take 
care of notification of tuberculosis and play the role of focal points for on-going 
communication. The national tuberculosis registry is electronic and case-based, and 
tuberculosis notification is web-based, which facilitates efficient reporting and timely 
update of clinical information. The public health system has public health nurses who 
are in charge of case management and contact tracing. More than 680 outreach 
workers have been hired to perform DOT. The public-public and public-private mix 
can be efficient and effective if collaboration between general health care facilities, 
local health authorities and Taiwan CDC operate smoothly, but could go wrong if 
monitoring, supervision and evaluation were lacking. 
 
Substantial progress in the fight against tuberculosis has been made after 
restructuring of the tuberculosis program. To further strengthen tuberculosis services 
in Taiwan, it is recommended that health authorities and Taiwan CDC: 1) pilot test 
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and subsequently scale up new diagnostics for the diagnosis of tuberculosis and 
drug-resistant tuberculosis; 2) investigate health system delay in the diagnosis and 
treatment of tuberculosis; 3) critically evaluate the quality and impact of DOT; 4) 
strengthen surveillance of drug-resistant tuberculosis; 5) address risk factors and 
social determinants of tuberculosis, and 6) seek consensus on the role of treatment 
of latent infection with M. tuberculosis in the tuberculosis program in Taiwan. 
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